Redhill Biopharma Ltd (NASDAQ:RDHL)

6.12
Delayed Data
As of Feb 16
 +0.19 / +3.20%
Today’s Change
4.30
Today|||52-Week Range
11.25
+19.07%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$130.2M

Company Description

RedHill Biopharma Ltd. is a biopharmaceutical company, which is focused on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. The company's gastrointestinal products include Donnatal and EnteraGam. Its clinical-stage pipeline includes TALICIA, RHB-104  BEKINDA, RHB-106, YELIVA, MESUPRON, and RIZAPORT. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Contact Information

RedHill Biopharma Ltd.
21 Ha'arba'a Street
Tel Aviv Tel Aviv 64739
P:(723) 541-3131
Investor Relations:

Employees

Shareholders

Other institutional15.04%
Mutual fund holders0.88%
Individual stakeholders--

Top Executives

Dror Ben-AsherChairman & Chief Executive Officer
Gilead RadayChief Operating Officer
Micha Ben-ChorinChief Financial Officer
Reza FathiSenior Vice President-Research & Development
Clara FehrmannDirector-Clinical Operations